Pancreatic Cancer Research

ResearcherAbramson Cancer CenterActive in the last 2 years

Thomas Benjamin Karasic

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9157-5392; OpenAlex author ID A5025028905. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
60
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 11

  1. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Co-author DOI 10.1038/s43018-026-01165-8↗
  2. Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses. Co-author DOI 10.1158/2767-9764.crc-26-0443↗
  3. A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer. Co-author DOI 10.1002/cncr.35936↗
  4. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-024-49915-5↗
  5. Effect of Stroma-directed Drugs in Combination with Chemotherapy Against Pancreatic Cancer- a Preclinical Study Co-author DOI 10.1101/2024.12.24.630138↗
  6. The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Ruca… Co-author DOI 10.1158/1078-0432.ccr-23-1467↗
  7. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. Co-author DOI 10.1016/s1470-2045(22)00369-2↗
  8. Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po.22.00060↗
  9. DWI Metrics Differentiating Benign Intraductal Papillary Mucinous Neoplasms from Invasive Pancreatic Cancer: A Study in GEM Models. Co-author DOI 10.3390/cancers14164017↗
  10. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, B… Co-author DOI 10.1200/jco.21.00003↗
  11. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2019.0684↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Peter James O'Dwyer · 7 shared papers, 2019–2026 · strength 1.06
  2. Mark H. O’Hara · 7 shared papers, 2019–2025 · strength 0.94
  3. Kim A. Reiss · 6 shared papers, 2019–2024 · strength 0.74
  4. Erica L. Carpenter · 4 shared papers, 2022–2025 · strength 0.62
  5. Rong Zhou · 3 shared papers, 2022–2026 · strength 0.54
  6. Mark Alan Rosen · 3 shared papers, 2022–2026 · strength 0.54
  7. Stephen Pickup · 3 shared papers, 2022–2026 · strength 0.54
  8. Mamta Gupta · 3 shared papers, 2022–2026 · strength 0.54
  9. Jacob Edward Till · 3 shared papers, 2022–2024 · strength 0.41
  10. Susan M. Domchek · 3 shared papers, 2021–2023 · strength 0.40
  11. Robert H. Vonderheide · 3 shared papers, 2021–2024 · strength 0.38
  12. Katherine L. Nathanson · 2 shared papers, 2021–2023 · strength 0.26
  13. Daniel D. Von Hoff · 2 shared papers, 2019–2026 · strength 0.26
  14. Jennifer Rachel Eads · 2 shared papers, 2022–2024 · strength 0.25
  15. Charles M. Vollmer · 1 shared paper, 2025 · strength 0.21
  16. John Peter Plastaras · 1 shared paper, 2025 · strength 0.21
  17. Andre A. Konski · 1 shared paper, 2025 · strength 0.21
  18. Uri Amit · 1 shared paper, 2025 · strength 0.21
  19. Edgar Ben‐Josef · 1 shared paper, 2025 · strength 0.21
  20. James M. Metz · 1 shared paper, 2025 · strength 0.21
  21. Kim A. Reiss-Binder · 1 shared paper, 2025 · strength 0.21
  22. Harshabad Singh · 1 shared paper, 2026 · strength 0.18
  23. ANDREA C Enzinger · 1 shared paper, 2026 · strength 0.18
  24. Jennifer Susan Thalappillil · 1 shared paper, 2026 · strength 0.18
  25. Douglas Adam Rubinson · 1 shared paper, 2026 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.